Report error Found 138 Enz. Inhib. hit(s) with all data for entry = 13227
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Iambic Therapeutics
US Patent
Iambic Therapeutics
US Patent
Affinity DataIC50: 200nMAssay Description:The radioactive signal generated from the aliquot of buffer solution was proportional to the amount of radiolabeled substrate produced, and which is ...More data for this Ligand-Target Pair




















